Exciting New Leads in the Fight against Malaria
News Jun 27, 2011
Malaria is a parasitic disease caused by Plasmodium spp. which still ravages many parts of the world, responsible for killing an estimated 781,000 people each year according to the World Health Organisation’s 2010 World Malaria Report. Treatment is frequently associated with the development of resistance and so new drug leads are always needed.
All of the compounds synthesized in this study showed remarkable in vitro activity in the low nanomolar range (0.2–3.7 nM) and several demonstrated promising oral activity in the P. berghei ANKA mouse model of malaria.
A preliminary study suggests that members of this series have improved metabolic stability compared with the parent compound RKA182 and these data coupled with the excellent activity profiles, low ClogP and high aqueous solubilities (e.g. >40mg/ml) make this series an exciting development in the struggle against malaria.
Reproduced by permission from The Royal Society of Chemistry from MedChemComm Blog at http://blogs.rsc.org/md/
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018